StockData
NAUTNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31

Nautilus Biotechnology, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026
$2.63+0.57 (+27.67%)

Close on Oct 19, 2026

Market cap
$334.37M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Oct 27, 2026, during market hours (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Jul 28, 2026During market hours$200.00K––
Q1 FY2026
Ended Mar 31, 2026
Apr 28, 2026After market close–––
Q4 FY2025
Ended Dec 31, 2025
Feb 26, 2026During market hours–––
Q3 FY2025
Ended Sep 30, 2025
Oct 28, 2025During market hours–––
Q2 FY2025
Ended Jun 30, 2025
Jul 31, 2025During market hours–––
Q1 FY2025
Ended Mar 31, 2025
Apr 29, 2025During market hours–$-0.13–
Q4 FY2024
Ended Dec 31, 2024
Feb 27, 2025During market hours–––
Q3 FY2024
Ended Sep 30, 2024
Oct 29, 2024During market hours–––
Q2 FY2024
Ended Jun 30, 2024
Jul 30, 2024During market hours–––
Q1 FY2024
Ended Mar 31, 2024
Apr 30, 2024During market hours–––
Q4 FY2023
Ended Dec 31, 2023
Feb 28, 2024Before market open–––

Company guidance

Outlook given with results on Feb 25, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
operating expenses increase202615% to 20% growthNew

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Nautilus Biotechnology filed with the SEC